Login to Your Account



Still 'Routes Forward' with Cancer Vaccine

Oxford BioMedica Loses TroVax Partner; Gains Cash, New Dea

By Jennifer Boggs


Thursday, April 30, 2009
A major pipeline reprioritization at Sanofi-Aventis left Oxford BioMedica plc without a partner for its late-stage cancer vaccine TroVax, but the UK company made up for it by signing an earlier-stage deal with Sanofi to develop gene-based therapies for ocular diseases. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription